VolitionRx Unveils Breakthrough Liquid Biopsy Tech with 99% Pure ctDNA
August 5, 2026 — VolitionRx's Capture-Seq liquid biopsy tech isolates >99% pure ctDNA, enabling early cancer detection and monitoring. Peer-reviewed study published, market potential $23B.